Mounjaro vs Orlistat: effectiveness, side effects and daily use
Mounjaro and orlistat are not an injection and tablet version of the same treatment. Mounjaro affects appetite-related hormone signalling; orlistat reduces absorption of some fat from food. The differences matter for daily life, side effects and what you can reasonably expect.
This comparison is about adult weight management. The prescription-dose orlistat evidence below is not interchangeable with evidence for lower-dose pharmacy products. Your prescriber or pharmacist needs to assess the actual product and your other medicines.
The practical differences
| Question | Mounjaro | Orlistat |
|---|---|---|
| Medicine | Tirzepatide; prescription injection | Orlistat; prescription 120 mg or lower-dose pharmacy products |
| Main mechanism | GIP/GLP-1 receptor activity affecting appetite and food intake | Acts in the gut to reduce fat absorption; not an appetite-suppressing injection |
| Routine | Once weekly, using a prescribed escalation and review plan | Tied to main meals that contain fat; product instructions matter |
| Typical practical concern | Injection routine, nausea and tolerance during treatment | Oily stools, urgency and planning meals around work or travel |
| Weight-management licence threshold | BMI at least 30, or at least 27 with a weight-related condition | Prescription Xenical: BMI at least 30, or at least 28 with associated risk factors |
The licence is not the NHS funding rule, and a lower BMI number is not evidence that a medicine is right for you. [1] [2] [3]
Read the units before believing the headline
These evidence summaries answer different questions. They must not be displayed as a head-to-head contest or turned into arbitrary “effectiveness scores”.
| Evidence | Result | What the number means |
|---|---|---|
| SURMOUNT-1; adults without diabetes; 72 weeks | Tirzepatide 5/10/15 mg: 15.0% / 19.5% / 20.9%; placebo 3.1% | Average percentage reduction from starting weight in a placebo-controlled trial with lifestyle support. |
| Xenical product information; pooled one-year trials | 3.2 kg greater mean weight loss with orlistat than placebo | An additional kilogram difference versus placebo—not total percentage weight loss. |
The tirzepatide trial was funded by Eli Lilly. The orlistat result is reported in the prescription product’s clinical evidence. Different populations, durations and outcome definitions mean the rows cannot give a reliable personal “extra weight I will lose” calculation. [4] [2]
The injection evidence makes substantial average weight reduction a legitimate topic for assessment. It does not make a tablet automatically pointless, nor does avoiding injections make orlistat risk-free. Ask which outcome is realistic for your circumstances and how it will be reviewed.
Orlistat changes the meal-time calculation
For prescription Xenical, the capsule is taken immediately before, during or up to one hour after a main meal. A dose is omitted when a meal is missed or contains no fat. Higher-fat meals can make gastrointestinal effects more troublesome. Follow your own product’s instructions rather than applying this automatically to another strength. [2]
Think about a working day: do you eat regular meals, can you access a toilet easily, and would you understand when a dose is not needed? Discuss how to maintain balanced nutrition rather than responding by skipping food or eliminating fat altogether.
Orlistat can affect fat-soluble vitamin absorption and interact with other medicines. Ask the pharmacist to check your full medication and supplement list, and whether vitamin advice is needed. NHS information distinguishes prescription Xenical from lower-dose products such as Alli and Orlos. [3]
Side effects: different does not mean trivial
For Mounjaro, nausea, vomiting and diarrhoea are recognised adverse effects. Other diabetes treatments may also need review. [1]
Do not dismiss severe, persistent abdominal pain as an ordinary side effect. Pain that may spread to your back, with or without vomiting, needs urgent medical assessment because pancreatitis is a possible serious reaction to these injections. [5]
For either treatment, contact your treating service when symptoms are persistent, severe or prevent normal eating and drinking. Do not assume that an unpleasant reaction proves the medicine is working. Read the patient leaflet supplied with the exact product.
Agree the review and stopping plan before you start
Prescription orlistat should be discontinued if at least 5% of initial body weight has not been lost after 12 weeks. That is a clinical review point, not a reason to take additional capsules. [2]
For the injection, ask when benefit and tolerability will be reviewed and what would justify continuing. Compare the full ongoing cost—including clinical support—not just the medicine’s introductory price. Keep a plan for interruptions and stopping, rather than assuming that a short course resolves everything permanently.
Do not add orlistat to an injection or switch products on the basis of this page. The MHRA advises discussing GLP-1 switches with a healthcare professional. Your existing prescription and other medicines belong in that conversation. [6]
A better decision than “jabs or tablets?”
- What does my medical history rule in or out?
- Can I follow this routine during an ordinary working week?
- Which side effects would require a call, a review or urgent help?
- What would count as enough benefit, and when will we decide?
- What support continues if the medicine changes or stops?
Keep the everyday plan with you
The Programme and My Timber provide a place for food, movement, goals and your own treatment history. A saved entry is a personal record—not a verified prescription or an instruction to change medicine.
See the Programme · Keep your history in My Timber · Understand NHS access
Common questions
Is Mounjaro better than orlistat?
The studies above do not provide a direct head-to-head comparison of these medicines. The tirzepatide result is a percentage reduction from starting weight; the orlistat figure is additional kilograms lost compared with placebo. They cannot be used to calculate your personal advantage from one medicine. Discuss expected benefit alongside side effects, day-to-day use and the review or stopping plan with your prescriber. [1] [2]
Is orlistat safer than Mounjaro?
Safety depends on your medical history, other medicines and tolerability. Mounjaro and orlistat have different side effects and precautions, so a capsule-versus-injection label cannot decide which is appropriate for you. Ask your prescriber to assess your circumstances and explain the warning signs and review plan. [1] [2]
Is orlistat a tablet version of Mounjaro?
No. The medicines have different mechanisms and routines. Orlistat acts on fat absorption in the gut; tirzepatide acts on GIP/GLP-1 receptors.
Does “3.2 kg” mean that is all someone loses on orlistat?
No. The cited pooled result is the mean additional loss compared with placebo after one year. It is not a total weight-loss forecast.
Can I take both together?
This comparison does not establish that a combination is appropriate or safe for you. Do not combine or switch them without the prescribing team assessing your treatment.
Sources and editorial responsibility
- Mounjaro: UK summary of product characteristics
- Xenical 120 mg: UK summary of product characteristics
- NHS: orlistat—uses, side effects and precautions
- Jastreboff et al., SURMOUNT-1, New England Journal of Medicine (2022)
- MHRA: strengthened warnings on acute pancreatitis, 29 January 2026
- MHRA: GLP-1 medicines—what you need to know
Product information and access arrangements can change. Use the original source and your treating service for decisions about your care. How SHIFT prepares articles · Report a factual correction.
What changed on 19 September 2026: Removed unsupported scores and the irrelevant semaglutide comparison; distinguished total percentage loss from placebo-adjusted kilograms and clarified prescription-dose orlistat use.